Evidence map›Paper›PMID 41184320›Full record

ArticleScientific reports2025

Differential effects of KRAS G-domain and hypervariable region mutants on cancer phenotypes.

James Allen D de Borja, Kim Denyse J Hao Lin, Daniel Angelo R Mirador, Alexandra Isabelle D Ang, Sidney Allen A Chua, Joanne Marie D Sytangco, Dennis L Sacdalan, Reynaldo L Garcia

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

James Allen D de BorjaDisease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Kim Denyse J Hao LinDisease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Daniel Angelo R Mirador *Disease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Alexandra Isabelle D Ang *Disease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Sidney Allen A Chua *Disease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Joanne Marie D Sytangco *Disease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Dennis L SacdalanDisease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines.
Reynaldo L GarciaDisease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City, 1101, Philippines. rlgarcia1@up.edu.ph.

Funding

National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman In-house GrantsPhilippine Council for Health Research and Development FP150025University of the Philippines System OVPAA-EIDR Code 06-008
6 · The paper itself

Abstract

Identification of tumor driver genes in cancer has led to the discovery of specific allelic variants that are useful as predictive or prognostic markers. In colorectal cancer (CRC), the K-Ras GTPase is one of the most mutated oncoproteins; therefore, understanding the functional consequences of its mutations will allow us to exploit allele-specific vulnerabilities and propose potential mechanisms of resistance in cancer therapeutics. In this study, cellular phenotypic consequences of the K-Ras mutants K117I, K117N, A146T, E168K, and K172T identified in Filipino young-onset CRC (YO-CRC) patients were assessed in HCT116, Caco-2, and NIH3T3 cells. In assays assessing DNA doubling in 2D cultures and viability in 3D multicellular spheroids, only K117I, K117N, and A146T exhibited enhanced proliferation and supported a tumor-like property of increased size and viability. All mutants exhibited increased cellular migration in HCT116 and NIH3T3 but not in Caco-2 cells. None of them caused resistance to apoptosis. Compared to wild type, K117I, K117N, and A146T increased Elk1 reporter activation as well as phospho-Erk and phospho-Akt levels. All mutants induced extensive cytoskeletal remodeling including formation of migratory and invasive structures. Finally, GDP docking simulations suggested increased nucleotide exchange as a mechanism of activation.

Indexed as

Colorectal NeoplasmsMutationProto-Oncogene Proteins p21(ras)AnimalsApoptosisCaco-2 CellsCell MovementCell ProliferationCell SurvivalHCT116 CellsHumansMiceNIH 3T3 CellsPhenotypeKRAS protein, humanProto-Oncogene Proteins p21(ras)EGFR pathwayK-RasYoung-onset CRC

Identifiers

PMID41184320
PMCPMC12583673

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.